Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
InDuRanS
NCT06810609Phase 2Recruiting
- Sponsor
- University Hospital Bonn
- Start
- Apr 2025
- Primary completion
- Dec 2029
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by University Hospital Bonn. Primary endpoint: Event-Free Survival at 2 years. Started Apr 2025; status: recruiting.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06810609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06810609.